Stock listing
ONCY Stock Price, News, Filings & Events — Oncolytics Biotech Inc.
Selected listing: ONCY · NASDAQ · USD · US
This page tracks Oncolytics Biotech Inc.'s ONCY:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ONCY:NASDAQ. ONCY:NASDAQ is the stock-level entry point for investors researching Oncolytics Biotech Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Oncolytics Biotech Inc. is a public company traded under the ticker ONCY in the American market. The company has a market capitalization of approximately $96.9 million. Oncolytics focuses on developing innovative therapies for cancer treatment.
- Ticker
- ONCY:NASDAQ
- Asset type
- Stock
- Market cap
- $95.1M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Oncolytics Biotech Inc. ONCY:NASDAQ stock context
This page tracks Oncolytics Biotech Inc.'s ONCY:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ONCY:NASDAQ. ONCY:NASDAQ is the stock-level entry point for investors researching Oncolytics Biotech Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Oncolytics Biotech Inc. is a public company traded under the ticker ONCY in the American market. The company has a market capitalization of approximately $96.9 million. Oncolytics focuses on developing innovative therapies for cancer treatment.
Latest news from Oncolytics Biotech Inc.
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
September 10, 2026
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
August 18, 2026
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
July 20, 2026
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
July 13, 2026
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
June 16, 2026
Oncolytics Biotech Inc. earnings calls
Oncolytics Biotech Inc. (ONCY) Q2 2025 Earnings Call
August 7, 2025 · Replay with transcript and chapters
Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call
May 14, 2025 · Replay with transcript and chapters
Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call
March 7, 2025 · Replay with transcript and chapters
Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call
November 12, 2024 · Replay with transcript and chapters
Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call
August 1, 2024 · Replay with transcript and chapters
Oncolytics Biotech Inc. (ONCY) Q1 2024 Earnings Call
May 9, 2024 · Replay with transcript and chapters
Research Oncolytics Biotech Inc.
Oncolytics Biotech Inc. investor report
Review AI stock analysis and investor report context for ONCY:NASDAQ.
Oncolytics Biotech Inc. company profile
View the public company page for Oncolytics Biotech Inc. on 6ix.
Oncolytics Biotech Inc. news
Read company news and market updates connected to Oncolytics Biotech Inc..
Oncolytics Biotech Inc. investor events
Find investor webinars, events, and replay context for Oncolytics Biotech Inc..